Crossmark

MASCC/ISOO Clinical Practice Statement: imaging and clinical laboratory tests in the diagnosis and management of medication-related osteonecrosis of the jaw

Crossref DOI link: https://doi.org/10.1007/s00520-025-09809-8

Published Online: 2025-09-13

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yarom, Noam

Abdalla-Aslan, Ragda

Migliorati, Cesar

Livshits, Elena

Rais, Mohammed Amir

Park, Wonse

Fregnani, Eduardo R.

Bektas-Kayhan, Kivanc

Epstein, Joel

Elad, Sharon
Funding

Funding for this research was provided by:

Tel Aviv University
License Information

Text and Data Mining valid from 2025-09-13

Version of Record valid from 2025-09-13
More Information

Article History

Received: 8 June 2025

Accepted: 24 July 2025

First Online: 13 September 2025

Declarations

:

: Not applicable.

: Not applicable.

: Not applicable.

: N Yarom, R Abdalla-Aslan, C Migliorati, E Livshits, RA Mohammed, W Park, ER Fregnani, K Bektas-Kayhan, and S Elad reported no relevant financial or non-financial interests to disclose. C. Migliorati is an adjudicator for Amgen Inc. JB. Epstein is a consultant for Rakuten, Sanotize Inc., Janssen, Neilsen Inc. J.B. Epstein is also the Associate Editor-in-Chief for Supportive Care in Cancer.

: The MASCC/ISOO OCSG Statements have been developed to facilitate expert-opinion-based management of oral complications of cancer and cancer therapy where high-quality evidence is lacking. Clinicians should use their judgment when making treatment decisions for individual patients. Statement authors and the MASCC/ISOO do not guarantee or take responsibility for the clinical outcomes in individual patients.

Document is current

Any future updates will be listed below